U.S. markets closed
  • S&P Futures

    4,280.75
    -5.75 (-0.13%)
     
  • Dow Futures

    33,955.00
    -26.00 (-0.08%)
     
  • Nasdaq Futures

    13,502.25
    -21.00 (-0.16%)
     
  • Russell 2000 Futures

    1,996.80
    -4.90 (-0.24%)
     
  • Crude Oil

    90.65
    +0.15 (+0.17%)
     
  • Gold

    1,768.80
    -2.40 (-0.14%)
     
  • Silver

    19.40
    -0.06 (-0.33%)
     
  • EUR/USD

    1.0083
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    2.8800
    -0.0130 (-0.45%)
     
  • Vix

    19.56
    -0.34 (-1.71%)
     
  • GBP/USD

    1.1916
    -0.0017 (-0.14%)
     
  • USD/JPY

    136.3130
    +0.4510 (+0.33%)
     
  • BTC-USD

    22,940.44
    -502.51 (-2.14%)
     
  • CMC Crypto 200

    545.08
    -12.66 (-2.27%)
     
  • FTSE 100

    7,541.85
    +26.10 (+0.35%)
     
  • Nikkei 225

    29,031.06
    +88.92 (+0.31%)
     

Biogen halts trial of its Alzheimer’s drug Aducanumab

In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Biogen decided to end its phase 3 trial of its Alzheimer’s drug Aducanumab. Heritage Capital LLC President Paul Schatz and Yahoo Finance’s Brian Sozzi, Scott Gamm and Alexis Christoforous break down the impact on the company.